|
1
|
Kyle RA and Rajkumar SV: Treatment of
multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma.
9:278–288. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sonneveld P and Broijl A: Treatment of
relapsed and refractory multiple myeloma. Haematologica.
101:396–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gonzalez-Paz N, Chng WJ, McClure RF, Blood
E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann
GJ, et al: Tumor suppressor p16 methylation in multiple myeloma:
Biological and clinical implications. Blood. 109:1228–1232. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mateos MV, García-Sanz R, López-Pérez R,
Moro MJ, Ocio E, Hernández J, Megido M, Caballero MD,
Fernández-Calvo J, Bárez A, et al: Methylation is an inactivating
mechanism of the p16 gene in multiple myeloma associated with high
plasma cell proliferation and short survival. Br J Haematol.
118:1034–1040. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reik W, Dean W and Walter J: Epigenetic
reprogramming in mammalian development. Science. 293:1089–1093.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baylin SB, Esteller M, Rountree MR,
Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA
methylation, chromatin formation and gene expression in cancer. Hum
Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jones PL and Wolffe AP: Relationships
between chromatin organization and DNA methylation in determining
gene expression. Semin Cancer Biol. 9:339–347. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fatemi M, Pao MM, Jeong S, Gal-Yam EN,
Egger G, Weisenberger DJ and Jones PA: Footprinting of mammalian
promoters: Use of a CpG DNA methyltransferase revealing nucleosome
positions at a single molecule level. Nucleic Acids Res.
33:e1762005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahuja N and Issa JP: Aging, methylation
and cancer. Histol Histopathol. 15:835–842. 2000.PubMed/NCBI
|
|
10
|
Jones PA and Baylin SB: The epigenomics of
cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Berdasco M and Esteller M: Aberrant
epigenetic landscape in cancer: How cellular identity goes awry.
Dev Cell. 19:698–711. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Asmar F, Punj V, Christensen J, Pedersen
MT, Pedersen A, Nielsen AB, Hother C, Ralfkiaer U, Brown P,
Ralfkiaer E, et al: Genome-wide profiling identifies a DNA
methylation signature that associates with TET2 mutations in
diffuse large B-cell lymphoma. Haematologica. 98:1912–1920. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sandoval J, Mendez-Gonzalez J, Nadal E,
Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A,
et al: A prognostic DNA methylation signature for stage I
non-small-cell lung cancer. J Clin Oncol. 31:4140–4147. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Esteller M: Cancer epigenomics: DNA
methylomes and histone-modification maps. Nat Rev Genet. 8:286–298.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Portela A and Esteller M: Epigenetic
modifications and human disease. Nat Biotechnol. 28:1057–1068.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen L, Kondo Y, Guo Y, Zhang J, Zhang L,
Ahmed S, Shu J, Chen X, Waterland RA and Issa JP: Genome-wide
profiling of DNA methylation reveals a class of normally methylated
CpG island promoters. PLoS Genet. 3:2023–2036. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Issa JP and Kantarjian HM: Targeting DNA
methylation. Clin Cancer Res. 15:3938–3946. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee ES, Issa JP, Roberts DB, Williams MD,
Weber RS, Kies MS and El-Naggar AK: Quantitative promoter
hypermethylation analysis of cancer-related genes in salivary gland
carcinomas: Comparison with methylation-specific PCR technique and
clinical significance. Clin Cancer Res. 14:2664–2672. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Chiappinelli KB, Guzzetta AA,
Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM,
Azad NS, et al: Immune regulation by low doses of the DNA
methyltransferase inhibitor 5-azacitidine in common human
epithelial cancers. Oncotarget. 5:587–598. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
González M, Mateos MV, García-Sanz R,
Balanzategui A, López-Pérez R, Chillón MC, González D, Alaejos I
and Miguel San JF: De novo methylation of tumor suppressor gene
p16/INK4a is a frequent finding in multiple myeloma patients at
diagnosis. Leukemia. 14:183–187. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Krämer A, Schultheis B, Bergmann J, Willer
A, Hegenbart U, Ho AD, Goldschmidt H and Hehlmann R: Alterations of
the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia.
16:1844–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Galm O, Yoshikawa H, Esteller M, Osieka R
and Herman JG: SOCS-1, a negative regulator of cytokine signaling,
is frequently silenced by methylation in multiple myeloma. Blood.
101:2784–2788. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chim CS, Liang R, Leung MH, Yip SF and
Kwong YL: Aberrant gene promoter methylation marking disease
progression in multiple myeloma. Leukemia. 20:1190–1192. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Amatori S, Bagaloni I, Donati B and
Fanelli M: DNA demethylating antineoplastic strategies: A
comparative point of view. Genes Cancer. 1:197–209. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Flotho C, Claus R, Batz C, Schneider M,
Sandrock I, Ihde S, Plass C, Niemeyer CM and Lübbert M: The DNA
methyltransferase inhibitors azacitidine, decitabine and zebularine
exert differential effects on cancer gene expression in acute
myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Durie BG, Harousseau JL, Miguel JS, Bladé
J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J,
Sonneveld P, et al: International uniform response criteria for
multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Draube A, Pfister R, Vockerodt M, Schuster
S, Kube D, Diehl V and Tesch H: Immunomagnetic enrichment of CD138
positive cells from weakly infiltrated myeloma patients samples
enables the determination of the tumor clone specific IgH
rearrangement. Ann Hematol. 80:83–89. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Herman JG, Graff JR, Myöhänen S, Nelkin BD
and Baylin SB: Methylation-specific PCR: A novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA.
93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Miguel San J, Schlag R, Khuageva N,
Dimopoulos M, Schpilberg O, Kropff M, Spicka I, Petrucci M, Palumbo
A, Samoilova O, et al: Bortezomib plus melphalan and prednisone for
initial treatment of multiple myeloma. N Engl J Med. 359:906–917.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Richardson PG, Sonneveld P, Schuster MW,
Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D,
Lonial S, Goldschmidt H, et al: Bortezomib or high-dose
dexamethasone for relapsed multiple myeloma. N Eng J Med.
352:2487–2498. 2005. View Article : Google Scholar
|
|
31
|
Greipp PR, Miguel San J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guillerm G, Depil S, Wolowiec D and
Quesnel B: Different prognostic values of p15(INK4b) and p16(INK4a)
gene methylations in multiple myeloma. Haematologica. 88:476–478.
2003.PubMed/NCBI
|
|
33
|
Galm O, Wilop S, Reichelt J, Jost E,
Gehbauer G, Herman JG and Osieka R: DNA methylation changes in
multiple myeloma. Leukemia. 18:1687–1692. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng G, Chen A, Hong J, Chae HS and Kim
YS: Methylation of CpG in a small region of the hMLH1 promoter
invariably correlates with the absence of gene expression. Cancer
Res. 59:2029–2033. 1999.PubMed/NCBI
|
|
35
|
Deng G, Chen A, Pong E and Kim YS:
Methylation in hMLH1 promoter interferes with its binding to
transcription factor CBF and inhibits gene expression. Oncogene.
20:7120–7127. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Depil S, Saudemont A and Quesnel B: SOCS-1
gene methylation is frequent but does not appear to have prognostic
value in patients with multiple myeloma. Leukemia. 17:1678–1679.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kyle RA and Rajkumar SV: Multiple myeloma.
N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roman-Gomez J, Jimenez-Velasco A,
Castillejo JA, Cervantes F, Barrios M, Colomer D, Heininger A and
Torres A: The suppressor of cytokine signaling-1 is constitutively
expressed in chronic myeloid leukemia and correlates with poor
cytogenetic response to interferon-alpha. Haematologica. 89:42–48.
2004.PubMed/NCBI
|
|
39
|
Li Z, Metze D, Nashan D, Müller-Tidow C,
Serve HL, Poremba C, Luger TA and Böhm M: Expression of SOCS-1,
suppressor of cytokine signalling-1, in human melanoma. J Invest
Dermatol. 123:737–745. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qu Y, Dang S and Hou P: Gene methylation
in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mateos MV, Garcia-Sanz R, López-Pérez R,
Balanzategui A, González MI, Fernández-Calvo J, Moro MJ, Hernández
J, Caballero MD, González M and Miguel San JF: p16/INK4a gene
inactivation by hypermethylation is associated with aggressive
variants of monoclonal gammopathies. Hematol J. 2:146–149. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guillerm G, Depil S, Wolowiec D and
Quesnel B: Different prognostic values of p15 (INK4b) and p16
(INK4a) gene methylations in multiple myeloma. Haematologica.
88:476–478. 2003.PubMed/NCBI
|
|
43
|
Ribas C, Colleoni GW, Felix RS, Silva
Regis MR, Caballero OL, Brait M and Bordin JO: p16 gene methylation
lacks correlation with angiogenesis and prognosis in multiple
myeloma. Cancer Lett. 26:247–254. 2005. View Article : Google Scholar
|
|
44
|
Chim CS, Fung TK, Cheung WC, Liang R and
Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma:
Implications for epigenetic activation of the Jak/STAT pathway.
Blood. 103:46302004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Esposito N, Colavita I, Quintarelli C,
Rodeo A, AL Peluso Luciano L, Picardi M, Vecchio L, Buonomo T and
Hughes T: SHP-1 expression accounts for resistance to imatinib
treatment in Philadelphia chromosome-positive cells derived from
patients with chronic myeloid leukemia.
|
|
46
|
Valentino L and Pierre J: JAK/STAT signal
transduction: Regulators and implications in hematological
malignancies. Biochem Pharmacol. 71:713–721. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang HF and Lai R: STAT3 in cancer-friend
or Foe? Cancers (Basel). 6:1408–1440. 2004. View Article : Google Scholar
|
|
48
|
de Fernández Larrea C, Martín-Antonio B,
Cibeira MT, Navarro A, Tovar N, Díaz T, Rosiñol L, Monzó M,
Urbano-Ispizua A and Bladé J: Impact of global and gene-specific
DNA methylation pattern in relapsed multiple myeloma patients
treated with bortezomib. Leuk Res. 37:641–646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Homedes N and Ugalde A: Availability and
affordability of new medicines in Latin American countries where
pivotal clinical trials were conducted. Bull World Health Organ.
93:674–683. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pichon-Riviere A, Garay OU, Augustovski F,
Vallejos C, Huayanay L, Mdel Bueno P, Rodriguez A, de Andrade CJ,
Buendía JA and Drummond M: Implications of global pricing policies
on access to innovative drugs: The case of trastuzumab in seven
Latin American countries. Int J Technol Assess Health Care.
31:2–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Goss PE, Lee BL, Badovinac-Crnjevic T,
Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza
C, Unger-Saldaña K, Ferreyra M, Debiasi M, et al: Planning cancer
control in Latin America and the Caribbean. Lancet Oncol.
14:391–436. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Amador-Medina LF, Lacayo-Leñero D,
Crespo-Solís E, Aguayo Á and Martínez-Baños D: Thalidomide and
dexamethasone induction therapy until best response in recently
diagnosed patients with multiple myeloma: Results from a pilot
study. Rev Invest Clin. 67:304–312. 2015.PubMed/NCBI
|
|
53
|
Knaul FM, González-Pier E, Gómez-Dantés O,
García-Junco D, Arreola-Ornelas H, Barraza-Lloréns M, Sandoval R,
Caballero F, Hernández-Avila M, Juan M, et al: The quest for
universal health coverage: Achieving social protection for all in
Mexico. Lancet. 380:1259–1279. 2012. View Article : Google Scholar : PubMed/NCBI
|
